Zenas BioPharma (ZBIO) EBITDA Margin (2023 - 2025)

Zenas BioPharma's (ZBIO) quarterly EBITDA Margin came in at 373.3% in Q1 2025, up 66.44% quarter-over-quarter from 1112.46% in Q4 2024.

Zenas BioPharma (ZBIO) EBITDA Margin (2023 - 2025) Analysis & Trends

Zenas BioPharma's EBITDA Margin history runs 3 years deep, the most recent figure standing at 373.3% for Q1 2025.

On a quarterly basis, EBITDA Margin changed N/A year-over-year to 373.3% in Q1 2025; TTM through Dec 2025 was 3830.57%, a 55283.0% decrease from a year earlier, with the FY2025 full-year figure at 3830.57%, down 55281.0% from the prior year.
EBITDA Margin rose to 373.3% in Q1 2025 per ZBIO's latest filing, from 1112.46% in the prior quarter.
Across five years, EBITDA Margin topped out at 71.25% in Q3 2023 and bottomed at 1112.46% in Q4 2024.
The 3-year median for EBITDA Margin is 373.3% (2025), against an average of 471.5%.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Zenas BioPharma	1.72 Bn	1.72 Bn	-	-

Download Data